In this review:
Pembrolizumab post-nephrectomy adjuvant therapy for RCC
Adjuvant mitotane in adrenocortical carcinoma patients
Atezolizumab and radiotherapy for advanced penile SCC
Sacituzumab govitecan + pembrolizumab for metastatic urothelial cancer
Rucaparib for metastatic urothelial carcinoma
Darolutamide + ADT and docetaxel for mHSPC
Continuing enzalutamide in mCRPC after progression on enzalutamide
PSMA PET and FDG PET predictors with 177Lu-PSMA-617 for mCRPC
Olaparib + abiraterone for mCRPC
Niraparib + abiraterone acetate and prednisone for mCRPC
Please login below to download this issue (PDF)